More from Chen -
11/16/18 -
Biotechs are in deep corrections. My sense is that this is a good time to buy quality stocks at deep discount. I recently asked a good friend of mine who is a very experienced biotech guy. If I put a gun to your head, which of the biotechs you would buy now? He told me it would be Acasti Pharma Inc. (ACST) and Viking Therapeutics, Inc. (VKTX). ACST is truly beyond reasoning here, he said. They are full funded to phase 3 results and raised at one dollar without warrants. Trial results will start to come out in Q3 of 2019. AMRN already recovered, they will likely get the FDA approval for expansion of label in 2019. Next time this year, with positive results that we are expecting, he strongly believes ACST will be the best in class and should be trading at least 5+. 11/28/18 -
I had a good meeting with Acasti Pharma Inc. (ACST) management yesterday. They came to New York to marketing their company finally. They are fully funded for the two phase 3 next year. The first phase 3 will finish enrollment in December and trial readout can come out as early as Q3 of 2019. The second trial is about 3 month behind and will be finished by the end of 2019. They are working on partnerships around the world and could bring extra money and collaborations. They are also working on other indications. They want to complete pre-clinical trials to support Capre lower the blood sugar. Lower A1C was one of the secondary end points of the current two phase 3 trials. They want to be able to include it in the label if the trial goes as they hoped. Oppenheimer plans to launch research coverage in January. I think once the tax loss selling is finished, excitement could build ahead of next year's data. On valuation, ACST is very very cheap. Even based on AMRN pre-REDUCE-IT half a billion market cap. It should worth that much, or $5/share. If the data is spectacular as we hoped, Capre can be the next Lipitor that took the majority of the market share WITHOUT an outcome study like REDUCE-IT. In that case, ACST can worth $20-50/share or more. After all, the patients want and deserve only the best.